Compare Davita Inc (DVA) vs Gitlab Inc (GTLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Gitlab Inc — how do they compare? Davita Inc trades at $178.1 (market cap $11.38B), while Gitlab Inc trades at $41.4 (market cap $7.11B). The key difference: Davita Inc is the larger of the two by market cap, and Gitlab Inc is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals.
| DVA | GTLB | |
|---|---|---|
Market Cap | $11.38B | $7.11B |
Sector | Health | Technology |
52-Week High | $240.96 | $51.04 |
52-Week Low | $103.87 | $19.42 |
Enterprise Value | $24.10B | $5.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.69, down slightly by 0.04% over the past day. The stock shows strong fundamental performance with consistent earnings beats in recent quarters, including Q2 2026 EPS of $4.02 versus $3.88 expected (Zacks Investment Research, 2026-08-04). However, technical indicators signal a bearish trend, with the price near key support at $182. Revenue growth remains steady, climbing to $13.64 billion in 2025, though net income margin dipped to 5.47%.
The outlook is mixed; analyst consensus leans bullish with a $232.25 price target (MarketBeat, 2026-08-05), but risks include reimbursement pressure and high debt levels. Investment appeal hinges on execution against guidance amid payer-mix challenges, with the current valuation offering potential upside if operational trends stabilize.
GitLab (GTLB) trades at $40.73, up 4.52% today, with a bullish technical signal from moving averages and a consensus analyst price target of $32.92. Recent earnings beats in Q3 2025 to Q1 2026 highlight strong execution, while revenue grew to $759.25 million in 2025. The stock's high P/E of 521.22 reflects growth expectations, but negative net income and cash flow pose challenges.
Outlook: Growth in DevSecOps and AI-driven software demand supports upside, but profitability risks and high valuation require caution. Key catalysts include continued revenue expansion and path to positive cash flow, while competition and execution missteps are primary risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →
